Summer 2026

Documentation & Artificial Intelligence Intern

Posted on 11/22/2025

Deadline 11/30/25
Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$21 - $46/hr

Monroe, GA, USA

In Person

On-site requirement: 4+ days/week at Covington site.

Category
AI & Machine Learning (1)

Get referred to Takeda

See people who can refer or advise you

Requirements
  • This position will be full-time and require 4+ days per week on-site at the Covington site.
  • Must be pursuing a Bachelor’s or Master’s degree in a STEM, Computer Science, Information Technology, Data Science, or related discipline.
  • A passion for technology, AI, and process improvement, with an interest in careful investigation and creative, analytical thinking.
  • Proven familiarity with AI concepts, programming (e.g., Python), and documentation preferred.
  • Must be authorized to work in the U.S. on a permanent basis without requiring sponsorship.
  • Must be currently enrolled in a degree program graduating December 2026 or later.
Responsibilities
  • Assisting with the organization, updating, and standardization of IT documentation to ensure accuracy and accessibility.
  • Supporting AI project development by preparing and maintaining project documentation, datasets, and results tracking.
  • Collaborating with team members to troubleshoot documentation gaps and streamline information flow.
Desired Qualifications
  • Hands-on experience with AI tools and applications, including exposure to data preparation, model interpretation, and results documentation.
  • Best practices for creating, updating, and standardizing IT documentation in a professional environment.
  • How to collaborate across teams to support both technical projects and process improvements.
  • Approaches to troubleshooting problems, analyzing outputs, and producing creative solutions under the guidance of experienced professionals.
  • Methods for applying AI and documentation skills to solve real-world challenges in an organization.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On 28 August 2026, FDA approved MIMRYLO for polycythemia vera.
  • On 5 August 2026, FDA approved ORZEYFUL; Takeda expects U.S. availability by November 2026.
  • Takeda's Q1 FY2026 revenue rose 10.2%, with new launches up 22.6%.

What critics are saying

  • The 18 May 2026 Amitiza verdict threatens a trebled bill above $2.5 billion.
  • Takeda announced 4,500 FY2026 job cuts, signaling expensive integration and execution strain.
  • ORZEYFUL still needs DEA scheduling; launch slippage would weaken 2026 growth momentum.

What makes Takeda unique

  • Takeda built first-in-class orexin and hepcidin platforms from Japanese discovery teams.
  • Its 2026 launches span narcolepsy, polycythemia vera, and dengue across major markets.
  • The company pairs global commercialization with deep experience in complex biologics and vaccines.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.

Yahoo Finance
Jul 30th, 2026
Takeda Pharmaceutical Q1 results on track as new launches offset mature product declines

Takeda Pharmaceutical reported first-quarter fiscal 2026 results aligned with its full-year outlook. Revenue totalled JPY 1.22 trillion, up 10.2% on an actual foreign-exchange basis but down 0.5% at constant exchange rates. Core operating profit reached JPY 358.9 billion, rising 11.5% on an actual FX basis. The company's core inline brands, representing 58% of total revenue, grew 2.3% at constant exchange rates. New launches accounted for 4% of revenue but grew 22.6%, supported by FRUZAQLA, LIVTENCITY, ADZYNMA and QDENGA. Takeda is preparing three product launches: ORZEYFUL for narcolepsy type 1, rusfertide for polycythemia vera, and zasocitinib for psoriasis. The company maintained its fiscal 2026 guidance and expects to generate JPY 650 billion to JPY 750 billion in free cash flow.

INACTIVE